ONC Oncolytics Biotech Inc
- 1.470
- -0.080-5.16%
Oncolytics Biotech Inc News
Maxim Group Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
Oncolytics Biotech: Promising Clinical Advancements and Strategic Partnerships Drive 'Buy' Rating
CCORF Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
Maxim Group Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
Buy Rating Affirmed for Oncolytics Biotech on Strong Phase 2 Results and Commercial Potential
Raymond James Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Raises Target Price to $2.58
CCORF Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
Buy Rating Affirmed for Oncolytics Biotech With Promising Developments in Cancer Therapy Trials
Oncolytics Biotech Analyst Ratings
CCORF Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
Optimistic Outlook for Oncolytics Biotech With Continued Buy Rating Amidst Promising Trial Results
Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY), R1 RCM (RCM) and Lumos Pharma (LUMO)
Oncolytics Biotech (ONCY) Receives a Buy From RBC Capital
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Oncolytics Biotech (ONCY) and Irhythm Technologies (IRTC)
Maxim Group Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
CCORF Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5
Buy Rating on Oncolytics Biotech Backed by Strong Clinical Trials and Strategic Partnerships
No Data